Anlotinib plus albumin-bound paclitaxel induction-maintenance for sorafenib-refractory radioiodine-refractory differentiated thyroid cancer: A case report and review of literature

Figure 1 Clinical timeline illustrating the disease trajectory, therapeutic interventions, and dynamic changes in thyroglobulin levels. The timeline demonstrates the clinical progression from the initial surgical intervention and radioactive iodine treatments to sequential targeted therapies. The red star marks a critical clinical juncture in February 2022, when significant radiological progression prompted the transition to the combined anlotinib and nab-paclitaxel regimen. This strategic intervention ultimately resulted in a sustained partial response and continuous decline in thyroglobulin levels. PTC: Papillary thyroid carcinoma; TSH: Thyroid-stimulating hormone; CT: Computed tomography; RAIR-DTC: Radioiodine-refractory differentiated thyroid cancer; RAI: Radioactive iodine; ns-Tg: Non-stimulated thyroglobulin; SD: Stable disease; PR: Partial response.